my quarter to today's you financial Thank and of report operational call. all on afternoon It Good us Matt. outstanding Thanks on for performance excellence. solid another everyone. pleasure is joining
our momentum to we short, it is In continue. expect and strong
exceeded seen several this the EBITDA to QX as years lofty on the not numerous I particularly business. am tremendous have hear for our for set team's company adjusted approaching proud you will levels motion. of enhancements expectations we the today, progress even As delivering due in
increase driven Wound focus competitive to and substantial Our space. was our on recent opportunity Surgical businesses the & in the our offerings decision in those highly markets by
sales Our gold That for be strong distinct us to growth gives years build, infrastructure. and will combination powerful foundation industry-leading advantages from to a operations outpace us come. from standard believe and technology what our which stem to enabling we market
and drove that opportunities the the the with anticipate on is front our of is capitalize needs The multiyear We company before first the growth numerous at strong half repeatable. that end disciplined to execution go-to-market strategy performance us. a focused base certainly
unfolding, on on we noteworthy accomplishments our you me Before some long-term from envision quarter. touch detail growth provide with of the plan let we second more more how the first
highest delivered approximately QX XX.X%, nice sales have quarterly we nearly the $XX.X sales profit performance step-up net four grew million, in to year-over-year improved years. to another sequentially. Gross XX.X% by net margin
million $X ended million, Adjusted was from EBITDA with improvement. $XX.X $X.X the cash, in the from almost a $XX.X million representing, quarter million of adjusted $XX EBITDA a of million year loss We up end QX. an ago, up
and Doug development next we And our the seasoned surgical and Doug of as Rice are ideally wound whose experience pleased Officer. strategic We him welcome project our executive a suspension considerable to pivot, new our is in the highly hones Knee healthcare of our growth. suited Osteoarthritis announced for makes which markets. Financial stage the Chief an to focus important team accomplished
contributions brief his already the value fact, seeing he's the on in In board. been time we of are
that is attractive Moreover, across I going has a foundation, can financial have business This products, level a the am to that any the entire in second of was win consecutive have high MiMedx. exceptional team an quarter that confident great by to performance market solid execution execute. at incredibly company. driven we opportunities of and
QX exceeded bottom, additional attention. EBITDA again, expectations adjusted our rates performance margin, While top financial to from our our
anticipated, EBITDA of is million As the dramatic return $XX.X net a represents margin scale. XX% on adjusted business QX starting sales. fairly improvement The with to generate
we However, out QX forma knee margin trial, our the in as significantly to on OA look start pro XX%. adjusted if the spend EBITDA have been would better of things excess
the lead funding free starting see, and As you business, cash we accelerate optionality our will value increase last flow can sheet as which, the generation, are quarter, to unlock to growth leverage mentioned I improve creation. in balance
practice, focus. provide key strategic elements quick a on three progress the my will is I As on our of update the company's
As time the order to ensure concentrating which long-term drive and growth in areas a in these we our are reminder, are and resources success.
in is Our during which product we the position enhancing quarter period service. geographically. & sites on Wound To our another end, build the excellence, priority by of markets to again and second leadership all portfolio that our growth commercial represented in of expanding experienced Surgical top once
wide in helping gain acceptance launched the in surgical grow in of year to sales last we market QX continued products by XX%. our two The September settings, to hospitals various
our and supporting wide efforts. range surgical We of our success believe of work significant medical are investments in the our with a surgical growing applications. a we body making real be markets, oral in sector enhanced affairs As in we refine greatly surgical approach to evidence will clinical research
growing reimbursement the the the saw at office companies on we part the quarterly to by trend list OIG's performance, another products for The price which QX register driven in in quarter, XX% being the second adhere likely private here CMS methodology. is positive continued year-over-year. sector, the ASP In guidance to strong we recorded into and
continue could transition year. this into the anticipate of support half to the growth second revenue with provide us We
and to later to product the this likely hope QX be another position in into new year, office in also setting. private launch We
positive published has but proposal CMS drive to the continue the schedule OIG's calendar few policy a CMS of modifications As this near skin you holds that have see weeks for how ago. substitutes enforcement which are reimbursed expect in period, the currently net would we any was any major XXXX, not not through at seen, may The us a least to to changes, proposed disruptive fee position policy current for would per year potentially indicates decided If XXXX make physician comment guidance. to term. be throughout
We as develop critical various safeguards and work payment. CMS strives will to that with and products these continue reimbursement abuse stakeholders over patient leading to to provide model a input ensures access against
we Finally, phase. we the as development were strides making Japan market encouraged through early are the we by in work
During to increased and the we of interest first-of-a-kind Japanese of continued market. this see level an the utilization product in in quarter,
to in such, ramp expect coming quarters. months adoption the and As we
to create the company. focus of With the drivers in for adjacent surgical our amniotic substitute our obvious to one opportunities now beyond business, additional growth firmly concentrated Our next strategic priority more offering tissue. is skin to on develop opportunities and expand is the markets wound
the substitute to the and up According data, market immediately allografts entire of with substitute addressable synthetics than total And our while and doubles XX% tissue our amniotic making commercial leveraging market our skin more market for amniotic offering skin of xenografts expansion account less balance. than beyond infrastructure.
have externally portfolio. As concerted both product the of expansion our toward we such, internally and efforts,
to leverage adjacent to market. commercial ways continue opportunities to look skin to and we the substitute our develop technology Additionally, for strength
continuous to is and objective process Our discipline rationalization improvement. expense build a around management, final corporate
indicate, take approach continues the results the As QX to hold within this organization.
our and and in from resulted operating gross efforts in operations another continue sequential Our we to improvement production and margin, get yields enhance expenses. leverage overall to efficiencies
second goals, of we've to a striving have of As get by is sales above reminder, year-end. surgical a the highlighted is which achieve and One we and two wound XX% to efficiency get G&A been XX% margin corporate below to contribution sales.
improvement an of scale both schedule. these resulting time. of QX, margin over ability I to will than execute continue targets further For our more plan, to well that achieved enhanced we anticipate we ahead on in and
It the great performance this another QX, team three-point on as certainly year. strategy we momentum the seems building executing turned in enter against the established and in
and plan the most to against Our our for continue identify drivers relevant growth business. to is execute
If healthcares franchise, create move this the we doubt I value opportunity ranks you have into no tremendous stick the build to most to admired this MiMedx formula, and companies. on will have
the end District it challenges. should that as with and XXth District States mention I'd of XXXX. class appeal United case against on in news, also were of the Court one from action to We in company of the the company past securities Northern lawsuit Georgia. affirming obviously the positive rest Court the others against of of punitive Appeals after quarter, by shortly The dismissal the put brought like of the ruled was our the favor receive potential this to stemming Circuit the to claims remaining glad largest
the Doug? Financial for to Now over financial inaugural Officer let call our call on MiMedx. is me results on detail more turn as Chief the what for Doug
